Kei Kushitani

1.4k total citations
65 papers, 959 citations indexed

About

Kei Kushitani is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Kei Kushitani has authored 65 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 11 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Kei Kushitani's work include Occupational and environmental lung diseases (26 papers), Lung Cancer Diagnosis and Treatment (19 papers) and Lung Cancer Treatments and Mutations (17 papers). Kei Kushitani is often cited by papers focused on Occupational and environmental lung diseases (26 papers), Lung Cancer Diagnosis and Treatment (19 papers) and Lung Cancer Treatments and Mutations (17 papers). Kei Kushitani collaborates with scholars based in Japan, Egypt and United Kingdom. Kei Kushitani's co-authors include Yukio Takeshima, Vishwa Jeet Amatya, Morihito Okada, Yoshihiro Miyata, Kouki Inai, Yasuhiro Tsutani, Takahiro Mimae, Yuichiro Kai, Takahiro Kambara and Masahiro Yoshimura and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Annals of Oncology.

In The Last Decade

Kei Kushitani

59 papers receiving 947 citations

Peers

Countries citing papers authored by Kei Kushitani

Since Specialization

Citations

This map shows the geographic impact of Kei Kushitani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Kushitani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Kushitani more than expected).

Fields of papers citing papers by Kei Kushitani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kei Kushitani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Kushitani. The network helps show where Kei Kushitani may publish in the future.

Co-authorship network of co-authors of Kei Kushitani

This figure shows the co-authorship network connecting the top 25 collaborators of Kei Kushitani. A scholar is included among the top collaborators of Kei Kushitani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kei Kushitani. Kei Kushitani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Role of guanylate-binding protein 1 in the proliferation of invasive lung adenocarcinoma cells 2025 ·Frontiers in Oncology ·Takashi Kumada, Takahiro Mimae, Norifumi Tsubokawa, Kei Kushitani, (unknown), Yoshihiro Miyata, (unknown)	1
2	Mitochondrial Metabolism as a Potential Novel Therapeutic Target for Lung Adenocarcinoma 2024 ·Anticancer Research ·Makoto Fujiwara, Takahiro Mimae, Kei Kushitani, Norifumi Tsubokawa, Yoshihiro Miyata, Yukio Takeshima, Morihito Okada	0
3	Long Non-coding RNALINC00152RequiresEZH2to Promote Mesothelioma Cell Proliferation, Migration, and Invasion 2023 ·Anticancer Research ·(unknown), Vishwa Jeet Amatya, Kei Kushitani, (unknown), (unknown), Yukio Takeshima	3
4	miR-142-3p Suppresses Invasion and Adhesion of Mesothelioma Cells by Downregulating ITGAV 2023 ·Pathobiology ·(unknown), Vishwa Jeet Amatya, Kei Kushitani, (unknown), (unknown), (unknown)	3
5	FOXM1 Promotes Mesothelioma Cell Migration and InvasionviaActivation of SMAD Signaling 2023 ·Anticancer Research ·(unknown), Vishwa Jeet Amatya, Kei Kushitani, Takahiro Kambara, (unknown), (unknown), Yukio Takeshima	0
6	Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27Kip1 2022 ·Frontiers in Oncology ·(unknown), Vishwa Jeet Amatya, Kei Kushitani, Takahiro Kambara, (unknown), (unknown), Yukio Takeshima	2
7	Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study 2022 ·Lung Cancer ·(unknown), Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Takahiko Kasai, Kei Kushitani, Yukio Takeshima, Kenzo Hiroshima, Akinori Iwasaki, Kazuki Nabeshima	3
8	Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features 2022 ·Annals of Diagnostic Pathology ·(unknown), Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Takahiko Kasai, Kenzo Hiroshima, Kei Kushitani, Yukio Takeshima, Kunimitsu Kawahara, Akinori Iwasaki, Kazuki Nabeshima	5
9	Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung 2021 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Masaoki Ito, Yasuhiro Tsutani, Ana Giménez‐Capitán, (unknown), (unknown), Cristina Aguado, Kei Kushitani, Yoshihiro Miyata, Koji Arihiro, Miguel Ángel Molina‐Vila, Rafael Rosell, Yukio Takeshima, Morihito Okada	11
10	Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung 2021 ·Translational Lung Cancer Research ·Yuichiro Kai, Vishwa Jeet Amatya, Kei Kushitani, Takahiro Kambara, (unknown), (unknown), Yasuhiro Tsutani, Yoshihiro Miyata, Morihito Okada, Yukio Takeshima	9
11	Segmentectomy vs Lobectomy for Clinical Stage IA Lung Adenocarcinoma With Spread Through Air Spaces 2020 ·The Annals of Thoracic Surgery ·Atsushi Kagimoto, Yasuhiro Tsutani, Kei Kushitani, Yuichiro Kai, Takahiro Kambara, Yoshihiro Miyata, Yukio Takeshima, Morihito Okada	35
12	Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma 2019 ·Journal of Cancer Research and Clinical Oncology ·Masaoki Ito, Yoshihiro Miyata, (unknown), (unknown), (unknown), Kyoko Ikeda, Kei Kushitani, Naoto Kishi, Yasuhiro Tsutani, Yukio Takeshima, Morihito Okada	7
13	Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma 2018 ·Modern Pathology ·Vishwa Jeet Amatya, Kei Kushitani, Yuichiro Kai, (unknown), Yoshihiro Miyata, Morihito Okada, Yukio Takeshima	22
14	miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma 2018 ·Frontiers in Oncology ·(unknown), Vishwa Jeet Amatya, Kei Kushitani, Yuichiro Kai, Takahiro Kambara, Yukio Takeshima	40
15	PIM1 knockdown inhibits cell proliferation and invasion of mesothelioma cells 2017 ·International Journal of Oncology ·(unknown), Vishwa Jeet Amatya, (unknown), Kei Kushitani, (unknown), Yukio Takeshima	13
16	Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma 2014 ·Journal of Thoracic and Cardiovascular Surgery ·Takahiro Mimae, Yasuhiro Tsutani, Yoshihiro Miyata, Tomoharu Yoshiya, Yuta Ibuki, Kei Kushitani, Yukio Takeshima, Haruhiko Nakayama, Sakae Okumura, Masahiro Yoshimura, Morihito Okada	30
17	Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer 2014 ·Journal of Thoracic and Cardiovascular Surgery ·Yasuhiro Tsutani, Yoshihiro Miyata, Kei Kushitani, Yukio Takeshima, Masahiro Yoshimura, Morihito Okada	32
18	The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma 2013 ·Journal of Thoracic and Cardiovascular Surgery ·Yasuhiro Tsutani, Yoshihiro Miyata, Takahiro Mimae, Kei Kushitani, Yukio Takeshima, Masahiro Yoshimura, Morihito Okada	79
19	Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma 2007 ·Pathology International ·Kei Kushitani, Yukio Takeshima, Vishwa Jeet Amatya, (unknown), (unknown), Kouki Inai	87
20	Aberrant methylation and loss of expression of O⁶‐methylguanine‐DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma 2005 ·Pathology International ·(unknown), Yukio Takeshima, (unknown), Kei Kushitani, Nobuoki Kohno, Kouki Inai	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact